Livedoid vasculitis - Livedoid Vaskulitishttps://en.wikipedia.org/wiki/Livedoid_vasculitis
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen. Et kann duerch Péng begleet ginn.
relevance score : -100.0%
References Livedoid vasculopathy: A review with focus on terminology and pathogenesis 36285834 NIH
Livedoid vasculopathy ass e seltenen Hautzoustand, charakteriséiert duerch schmerzhafte Geschwüren, déi ëmmer erëm op den ënneschte Been kommen.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy: A review of pathogenesis and principles of management 27297279Livedoid vasculopathy ass e seltenen Hautbedingung, deen widderhuelend Geschwüren op den ënneschte Been verursaacht, déi blass Narben hannerléisst, bekannt als Atrophie blanche. Wärend déi exakt Ursaach nach ëmmer onkloer ass, gëtt ugeholl datt erhéicht Bluttgerinnung (hypercoagulability) den Haaptfaktor ass, mat Entzündung déi eng sekundär Roll spillt. Faktoren, déi zu der Koagulatioun bäidroen, enthalen déi folgend - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Bei Biopsien weist d'Conditioun Bluttgerinnung bannent de Gefässer, Verdickung vun de Gefässmaueren a Narben. D'Behandlung beinhalt eng multi-pronged Approche déi sech op d'Vermeidung vu Bluttgerinnung mat Medikamenter konzentréiert wéi Anti-Platz-Drogen, Bluttdinner, a fibrinolytesch Therapie. Verschidde Medikamenter kënne fir dës Hautkonditioun benotzt ginn - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid Vasculopathy 32644463 NIH
Livedoid vasculopathy ass e seltenen Zoustand wou Läsionen op béide Been optrieden. D'Bildung vu Bluttverhënnerungen a klenge Bluttgefässer gëtt ugeholl datt se verursaacht ginn duerch verstäerkte Koagulatioun a reduzéierter Clot Decompte, zesumme mat Schied un der Gefässfërderung. Et ass méi heefeg bei Weibercher, virun allem tëscht Alter 15 a 50. Fëmmen opzehalen, Wonnen ze këmmeren, a Medikamenter wéi Bluttdinner an Antiplatelet Medikamenter ze benotzen waren effektiv.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.